ARTICLE | Finance
Pfizer plugs back in
Why Pfizer earmarked 25% of $600M venture allocation to back neuroscience plays
June 8, 2018 3:32 PM UTC
While Pfizer Inc. (NYSE:PFE) retreated from neuroscience R&D in January, the pharma hasn’t cut the cord yet. Ramped up allocations to neuroscience out of its latest $600 million venture investment give Pfizer the ability to assess the right time to re-enter the space.
Through Pfizer Ventures, the pharma plans to allocate about $150 million of the new funds to early stage neuroscience companies...
BCIQ Company Profiles